PORTFOLIO
PORTFOLIO COMPANIES
COMPANY PROFILE
Cellular technology breakthrough for clear vision of the future.
Cellusion Inc. is a regenerative medicine startup developing a novel cell therapy product for bullous keratopathy, applied about half of corneal transplantation cases. The company is pursuing to commercialize CLS001, an iPSC derived corneal endothelial substitute cell, invented by co-founder and CEO, Dr. Hatou. A First-in-Human investigator-initiated clinical study of CLS001 is planned to begin in 2022.
COMPANY STORY
Origin
Three professors in Keio university, Dr. Hatou, Dr. Tsubota and Dr. Shimura, founded Cellusion in 2015 to commercialize corneal regenerative medicine therapies to solve the unmet medical needs faced in clinical settings.
Strength
-Proprietary manufacturing method from iPSC to corneal endothelial substitute cells in direct differentiation induction manner.
-Robust manufacturing process, stable product quality and economically-viable CoGs by utilizing allogenic iPSC as raw material.
-Off-the-shelf cell therapy platform enabled by proprietary cryopreservation.
-Robust manufacturing process, stable product quality and economically-viable CoGs by utilizing allogenic iPSC as raw material.
-Off-the-shelf cell therapy platform enabled by proprietary cryopreservation.
UTEC’s value add
Financing strategy and talent recruitment
-
iPS derived corneal endthelial substitute cells
-
Corneal endothelial cells regenerative therapy
